COMPARABLE PROFITS METHOD / TRANSACTIONAL NET MARGIN METHOD ANALYSIS
Penterra Biopharma International DAC Operating Margins
Tax Years 2017–2020
Prepared by
Whitmore Valuation Group LLC 200 Ashbury Asset Advisors, Suite 700 Boston, MA 02109
Under Direction of
Calderwood & Harkness LLP Pursuant to Kovel Engagement
November 2022
Prepared for:
Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
Attention: Leonard Cross, Partner
Garrett Simmons, Associate
Lead Economist: Dr. Helena Vasquez, Ph.D., Managing Director Supporting Economist: Dr. Rohan Chakrabarti, Ph.D., Senior Director
Engagement Reference: C&H Matter Number 1018-00009 Kovel Letter Reference 1018-00009-KV, executed June 20, 2022
PRIVILEGED AND CONFIDENTIAL — Prepared at the direction of counsel in anticipation of litigation. Attorney-Client Privilege / Work Product Doctrine. Not to be disclosed without express authorization of Calderwood & Harkness LLP.
Right-click to update Table of Contents
I. Executive Summary
I.A. Purpose of the Report
Whitmore Valuation Group LLC ("WVG") has been retained under a Kovel arrangement by Calderwood & Harkness LLP ("C&H"), outside tax counsel to Penterra Pharmaceuticals Corp. ("PPC," EIN 22-3741856), to provide independent economic analysis in connection with the Internal Revenue Service ("IRS") Large Business & International Division examination (Exam Team ID LB&I-NE-TP-2022-00641) of PPC's federal income tax returns (Forms 1120) for tax years ("TY") 2017, 2018, 2019, and 2020. The examination was opened on May 16, 2022, and the IRS has challenged the transfer pricing methodology used in connection with PPC's Irish intellectual-property-holding structure, specifically the intercompany arrangements between PPC and Penterra Biopharma International DAC ("PBI"), PPC's wholly owned indirect subsidiary organized under the laws of Ireland.
The purpose of this report is to present an analysis under the Comparable Profits Method ("CPM"), as described in Treasury Regulations § 1.482-5, and the closely related Transactional Net Margin Method ("TNMM"), as described in the Organisation for Economic Co-operation and Development ("OECD") Transfer Pricing Guidelines, Chapter II, testing whether PBI's operating margins for TY 2017 through 2020 fall within an arm's-length range. The CPM and TNMM are profit-based transfer pricing methods that evaluate whether the reported operating results of the tested party — here, PBI — are consistent with the results that would be achieved by uncontrolled comparable companies operating under comparable economic circumstances.
This report has been prepared at the direction of counsel and is submitted in connection with the pending IRS examination. The analysis contained herein is protected by the attorney-client privilege and work product doctrine pursuant to the Kovel engagement agreement executed between C&H and WVG on June 20, 2022 (Kovel Letter Reference 1018-00009-KV).
I.B. Summary of Conclusion
Based on the analysis described in this report, WVG identified 22 comparable independent companies functioning as distributors, IP-holding companies, and commercialization principals in the pharmaceutical and life sciences sector. These comparable companies were identified through a rigorous, multi-step quantitative and qualitative screening process applied to publicly available financial databases, as described in detail in Section IV and Appendix C of this report.
WVG's analysis demonstrates that PBI's operating margins for each of the four tax years at issue (TY 2017, 2018, 2019, and 2020) fall within the interquartile range ("IQR") of operating margins earned by the 22 comparable companies. This finding confirms that PBI's profit levels are consistent with the arm's-length standard under Internal Revenue Code ("IRC") § 482 and Treasury Regulations § 1.482-5, and further confirms that the controlled transactions between PPC and PBI produce results consistent with what unrelated parties operating at arm's length would achieve.
The analysis further demonstrates that the IRS's proposed net adjustments of $380.4 million across TY 2017–2020 would depress PBI's operating margins below the 25th percentile of the comparable company set, thereby producing a non-arm's-length result that is inconsistent with the economic reality of PBI's functions, assets, and risks.
The CPM/TNMM analysis presented in this report supports the position that the cost-sharing arrangement ("CSA") between PPC and PBI, and the related intercompany royalty arrangement for legacy intellectual property, produce results that are consistent with what unrelated parties operating at arm's length would achieve. This report provides a complementary analytical method (alongside the Comparable Uncontrolled Transaction ("CUT") analysis for royalties and the income method / Discounted cash flow ("DCF") analysis for the platform contribution transaction ("PCT") valuation, each prepared in separate WVG reports) to test PBI's arm's-length profitability.
I.C. Overview of IRS Positions Being Addressed
The IRS has proposed net adjustments totaling approximately $380.4 million across TY 2017–2020, comprising the following components:
(a) CSA cost-sharing adjustments of $235.01 million. The IRS proposes to increase PBI's cost-sharing percentage by approximately 8 to 12 percentage points for each tax year, resulting in additional cost-sharing payments from PBI to PPC that would reduce PBI's reported operating income.
(b) Royalty rate adjustments of $188.04 million. The IRS proposes to increase the legacy intellectual property royalty rate from 4.5% to 11.0% of net sales for the non-Americas territory, resulting in additional royalty payments from PBI to PPC.
(c) Correlative offset of ($42.65 million). The IRS has allowed a partial correlative offset to avoid double-counting of certain adjustments.
In addition to the proposed monetary adjustments, the IRS has challenged PBI's economic substance, arguing that key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions remained in the United States and were performed by PPC personnel, rather than by PBI personnel in Ireland. The IRS contends that PBI's role as IP owner and CSA participant is not supported by sufficient economic substance, and that PBI is effectively a conduit entity that does not perform the functions or bear the risks commensurate with the income it reports.
This CPM/TNMM analysis addresses each of these IRS positions by demonstrating that PBI's reported profit levels are consistent with the arm's-length standard and that the IRS's proposed adjustments would produce non-arm's-length outcomes. Detailed rebuttals of each IRS position are presented in Section VII of this report.
II. Background and Factual Overview
II.A. Penterra Pharmaceuticals Corp. — Overview
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on the development, manufacture, and commercialization of innovative therapies in the therapeutic areas of oncology, immunology, and rare-disease therapeutics.
PPC's executive leadership team includes the following key officers relevant to this engagement:
• Chief Executive Officer: Catherine Falk
• Chief Financial Officer: Rajesh Iyer
• General Counsel: Deborah Staines
• Vice President, Global Tax: Marcus Whitfield
For fiscal year ("FY") 2020, PPC reported annual consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC employs approximately 14,500 individuals globally, with significant operations in the United States, Ireland, and various other jurisdictions across Europe, Asia-Pacific, and the Americas.
PPC's independent auditor and tax return preparer is Crestfield & Associates LLP. The Engagement Partner for PPC's audit is Martin Ogilvy, CPA, and the Transfer Pricing Partner responsible for PPC's contemporaneous transfer pricing documentation is Susan Lam, CPA. Crestfield & Associates has served as PPC's outside auditor since 2008 and has prepared PPC's contemporaneous transfer pricing documentation for all tax years at issue.
II.B. PPC Group Structure
PPC's corporate structure relevant to this analysis is as follows:
1. Penterra Pharmaceuticals Corp. ("PPC") — United States, Delaware corporation. PPC is the ultimate parent entity and the U.S. taxpayer under examination.
2. Penterra Holdings Luxembourg S.à r.l. ("PHL") — Luxembourg private limited liability company, registered at 14, rue Aldringen, L-1118 Luxembourg, Luxembourg (Luxembourg Registre de Commerce et des Sociétés Number B 168452). PHL is a wholly owned subsidiary of PPC and is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treasury Regulations § 301.7701-3. PHL serves as an intermediate holding company in the group structure.
3. Penterra Biopharma International DAC ("PBI") — Ireland, Designated Activity Company. PBI is a wholly owned subsidiary of PHL and, therefore, an indirect wholly owned subsidiary of PPC. PBI is the tested party in this CPM/TNMM analysis and is described in detail in Section II.C below.
4. Penterra Manufacturing Ireland Ltd. ("PMI") — Ireland, private limited company, registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland (Irish Companies Registration Office Number 512347). PMI is a wholly owned subsidiary of PBI and operates as a contract manufacturer of oncology and immunology biologics for non-Americas markets under a cost-plus 8% arrangement with PBI. PMI employs approximately 620 individuals at its manufacturing facility in Ringaskiddy, Co. Cork.
The intercompany arrangements among these entities — including the CSA between PPC and PBI, the legacy IP royalty arrangement between PPC and PBI, and the contract manufacturing arrangement between PBI and PMI — are described in Section II.D below.
II.C. Penterra Biopharma International DAC — The Tested Party
Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under the laws of Ireland. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish Tax Reference Number is 3218764T, and Aidan Naughton serves as Managing Director.
PBI was incorporated on March 15, 2012, and the CSA between PPC and PBI became effective on July 1, 2012. PBI was established to serve as the IP-holding company and principal for non-Americas commercialization of PPC's pharmaceutical product portfolio. In this capacity, PBI manages contract manufacturing and distribution arrangements across the Europe, Middle East, and Africa ("EMEA") and Asia-Pacific ("APAC") regions.
For FY 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's headcount has grown substantially since its incorporation, increasing from 52 employees at the time of incorporation in 2012 to 185 employees as of the end of FY 2020. PBI's employees are predominantly based in Dublin and include professionals in regulatory affairs, medical affairs, commercial strategy, supply-chain management, finance, legal, and general administration.
PBI's Irish tax advisor is Thornbury & Keogh, Chartered Tax Advisors, Dublin, with Ciarán Thornbury serving as Lead Partner. PBI is subject to Ireland's standard corporation tax rate of 12.5% on trading income. From FY 2016 forward, PBI has claimed benefits under Ireland's Knowledge Development box ("KDB") regime, which provides an effective tax rate of 6.25% on qualifying income derived from qualifying intellectual property assets.
PBI maintains office space of approximately 18,000 square feet at Sandyford Business Park in Dublin, which houses the company's operational, regulatory, medical affairs, commercial, and administrative personnel. PBI's primary banking relationship is with Glenmore Bank Ireland plc, through which PBI maintains its operational accounts, foreign currency hedging facilities, and cash management arrangements.
II.D. Intercompany Arrangements
II.D.1. Cost-Sharing Arrangement
PPC and PBI entered into a Cost-Sharing Arrangement effective July 1, 2012, pursuant to Treasury Regulations § 1.482-7. Under the CSA, PBI acquired rights to develop and exploit PPC's pharmaceutical intellectual property portfolio outside the Americas (i.e., in the EMEA and APAC regions) in exchange for two forms of consideration:
(a) Platform Contribution Transaction ("PCT") Payment. PBI made a one-time PCT payment of $312 million to PPC at the inception of the CSA, representing arm's-length consideration for PPC's pre-existing platform contributions (including the value of PPC's then-existing IP portfolio, workforce in place, and other resources made available to PBI at the outset of the CSA). The PCT payment was valued using an income method / DCF analysis, as documented in a separate WVG report (pct-valuation-report.docx).
(b) Ongoing Cost-Sharing Payments. PBI makes ongoing cost-sharing payments proportional to its share of reasonably anticipated benefits ("RAB") from the intangible development activities performed under the CSA. PBI's share of annual qualified R&D costs for the years at issue was as follows:
PBI's RAB share increased over the 2017–2020 period, reflecting the growing proportion of reasonably anticipated benefits attributable to the non-Americas territory as PBI expanded its commercial operations and as PPC products gained market share in EMEA and APAC markets. The RAB shares were determined using a revenue-based allocation key, consistent with the methodology specified in the CSA agreement and PPC's contemporaneous documentation.
II.D.2. Legacy IP Royalty Arrangement
In addition to the CSA, PBI licenses certain legacy pharmaceutical compounds from PPC. These legacy compounds are products that were developed and commercialized prior to the effective date of the CSA (July 1, 2012) and are therefore not covered by the CSA's cost-sharing provisions. Under the legacy IP license agreement, PBI pays PPC a royalty of 4.5% of net sales for the non-Americas territory.
The following table presents legacy compound net sales and royalty payments for the years at issue:
As the legacy compounds are mature products facing generic competition and declining market share in non-Americas territories, the associated net sales and royalty payments have declined steadily over the 2017–2020 period. The arm's-length nature of the 4.5% royalty rate is independently supported by the CUT analysis prepared in a separate WVG report (cut-analysis-royalty-report.docx), which identifies 14 comparable pharmaceutical license agreements with an IQR of 3.1% to 6.8% (median 4.4%).
II.D.3. Contract Manufacturing Arrangement
PBI engages Penterra Manufacturing Ireland Ltd. ("PMI") as its contract manufacturer for oncology and immunology biologics intended for non-Americas markets. Under the contract manufacturing agreement, PMI is compensated on a cost-plus basis at a markup of 8% over its fully loaded costs of production. This compensation structure reflects PMI's limited-risk contract manufacturer profile: PMI does not own the intellectual property underlying the products it manufactures, does not bear market risk or inventory risk for finished goods, and performs its manufacturing activities under the direction and supervision of PBI.
The cost-plus 8% markup was determined to be arm's-length based on a benchmarking study of comparable contract manufacturing arrangements in the pharmaceutical industry, as documented in PPC's contemporaneous transfer pricing documentation prepared by Crestfield & Associates.
II.E. Key Products and Revenue Data
PPC's product portfolio includes several significant pharmaceutical products that are commercialized globally. The following table summarizes the key products and their revenue contribution for FY 2020:
Veritaxol is PPC's largest revenue-generating product and is classified as a "Blockbuster" therapy, having exceeded $1 billion in global annual sales since 2016. Veritaxol is a first-in-class monoclonal antibody indicated for the treatment of certain advanced solid tumors, and it represents PPC's single most significant commercial asset.
Imvara is a biologic therapy indicated for the treatment of moderate-to-severe autoimmune conditions, including rheumatoid arthritis and inflammatory bowel disease. Imvara was approved in the European Union in 2014 and has achieved significant market penetration across EMEA markets.
Cerulon is an enzyme replacement therapy indicated for the treatment of a specific rare metabolic disorder. While Cerulon generates lower absolute revenue than Veritaxol or Imvara, it commands premium pricing in its niche indication and contributes meaningfully to PBI's overall profitability.
In addition to these three principal products, PBI commercializes a portfolio of legacy compounds (pre-2012 vintage) in non-Americas territories, as described in Section II.D.2 above. Revenue from legacy compounds has declined over the period under examination due to loss of exclusivity and generic competition.
II.F. PBI's Functions, Assets, and Risks
The following is a summary of PBI's functions, assets, and risks relevant to the CPM/TNMM analysis. A comprehensive functional analysis has been prepared separately and is documented in the functional analysis reports prepared by WVG (functional-analysis-report.docx and functional-analysis-report-updated.docx).
Functions. PBI employs regulatory, medical-affairs, commercial-strategy, and supply-chain personnel at its offices in Dublin. PBI manages regulatory submissions and marketing authorization applications across 68 non-Americas country markets, including all 27 European Union member states, the United Kingdom, Switzerland, Japan, South Korea, Australia, and numerous other OECD and non-OECD jurisdictions. PBI makes independent commercial decisions regarding pricing, market entry, distribution partner selection, product launch sequencing, and marketing strategy in its territories. PBI's cumulative regulatory expenditures on submissions for non-Americas markets during the 2017–2020 period totaled €47.2 million.
Corporate Governance. During the 2017–2020 period, PBI's board of directors held 42 board meetings in Dublin, consisting of regular quarterly meetings and special sessions convened to address significant commercial and strategic matters. The board meetings were attended in person by PBI's Ireland-based directors and officers, and minutes of each meeting reflect substantive discussion and decision-making on matters including product pricing, regulatory strategy, market entry decisions, capital allocation, and risk management.
Employees and Interviews. PBI employed 185 individuals as of the end of FY 2020, an increase from 52 employees at the time of incorporation in 2012. In connection with C&H's preparation of PPC's defense, 12 key PBI employees were interviewed by C&H attorneys to document their substantive decision-making authority, functional contributions, and day-to-day responsibilities. These interviews confirmed that PBI personnel exercise genuine, independent judgment and authority over the commercial and regulatory activities within their respective areas of responsibility.
Assets and Capital Expenditures. PBI holds significant intangible assets, including rights under the CSA to exploit PPC's pharmaceutical IP portfolio outside the Americas, as well as licensed rights to legacy compounds. PBI also holds tangible assets including its office facilities at Sandyford Business Park (approximately 18,000 square feet), information technology infrastructure, and equipment. PBI's capital expenditures on regulatory submissions, IT infrastructure, and commercial operations support its characterization as an IP-holding principal with significant DEMPE functions.
Risks. PBI bears market risk for non-Americas territories, including demand risk, competitive risk, and reimbursement/pricing pressure risk arising from government pricing regulations and health technology assessment processes in its 68 country markets. PBI also bears regulatory risk (the risk of approval delays, label restrictions, or adverse post-marketing requirements), foreign exchange risk (arising from euro-denominated operations with sales in multiple currencies), credit risk (accounts receivable from distribution partners), and product liability risk (shared with PPC under intercompany indemnification agreements).
III. Applicable Legal and Regulatory Framework
III.A. IRC § 482 and the Arm's-Length Standard
Section 482 of the Internal Revenue Code grants the Secretary of the Treasury broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses.
The regulations under IRC § 482 implement the arm's-length standard, which is the fundamental principle governing the pricing of controlled transactions. Treasury Regulations § 1.482-1(b)(1) provides that "[i]n determining the true taxable income of a controlled taxpayer, the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer." The arm's-length standard, as articulated in Treasury Regulations § 1.482-1(d), requires that the results of controlled transactions be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
Critically, the regulations establish a "best method rule" under Treasury Regulations § 1.482-1(c), which provides that the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. The best method rule does not create a hierarchy among the specified transfer pricing methods; rather, the selection of a method depends on the relative reliability of the method as applied to the facts and circumstances of the particular case. Factors relevant to the best method determination include the degree of comparability between the controlled transaction and comparable uncontrolled transactions, and the quality of the data and assumptions used in the analysis.
In the context of this report, WVG applies the CPM as the primary method to evaluate whether PBI's operating results fall within the arm's-length range. As discussed below, the CPM is the most reliable method for testing PBI's overall profitability, given the availability of comparable companies performing similar functions and bearing similar risks. The CPM/TNMM analysis is complementary to the CUT analysis for the legacy IP royalty and the income method/DCF analysis for the PCT valuation, each of which is addressed in separate WVG reports.
III.B. Comparable Profits Method — Treas. Reg. § 1.482-5
The Comparable Profits Method, as described in Treasury Regulations § 1.482-5, evaluates whether the amount charged in a controlled transaction is arm's length by reference to objective measures of profitability (profit level indicators, or "PLIs") derived from uncontrolled taxpayers that engage in similar business activities under similar circumstances. Under the CPM, the operating result of the "tested party" — the controlled taxpayer whose profitability is tested — is compared to the operating results of comparable uncontrolled companies.
The CPM evaluates profitability using one or more PLIs. Treasury Regulations § 1.482-5(b)(4) identifies several PLIs that may be appropriate depending on the facts and circumstances, including:
(a) Operating margin (operating income divided by net revenue), which measures the relationship between revenue and the costs of performing the tested party's functions;
(b) Berry ratio (gross profit divided by operating expenses), which is particularly useful when the tested party's gross profit is not significantly affected by the value of intangible property or other factors that are not comparable to those of the uncontrolled comparables;
(c) Return on assets (operating income divided by operating assets), which measures the efficiency of capital deployment and is appropriate when the tested party employs significant capital assets in its operations.
The selection of the appropriate PLI depends on the nature of the tested party's functions, the availability and reliability of data, and the degree to which the PLI is affected by factors that are not adequately accounted for in the comparability analysis. In this analysis, WVG selects operating margin as the primary PLI, with Berry ratio and return on assets employed as confirmatory measures, as discussed in Section IV.B.
The CPM requires that the tested party be the controlled participant whose profitability can be most reliably tested against comparable uncontrolled companies. In the present case, PBI is selected as the tested party because its functions — IP-holding, regional commercialization principal, regulatory management, and supply-chain coordination — can be benchmarked against independent comparable companies performing similar functions. PPC, as the more complex party with unique, high-value intangible property (drug development capabilities, core R&D operations, and the associated workforce in place), is not amenable to reliable benchmarking under the CPM.
III.C. Transactional Net Margin Method — OECD Guidelines
The Transactional Net Margin Method ("TNMM") is described in the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 revision, and as updated in the 2022 revision), Chapter II, paragraphs 2.58 through 2.107. The TNMM examines the net profit margin relative to an appropriate base (such as revenue, costs, or assets) that a taxpayer realizes from a controlled transaction or group of controlled transactions.
The TNMM and the CPM are closely related methods. Both evaluate the profitability of a tested party by comparing its profit level to that of comparable uncontrolled companies. The principal difference between the two methods is one of nomenclature and regulatory provenance: the CPM is the terminology used under U.S. Treasury Regulations, while the TNMM is the terminology used under the OECD Guidelines. The underlying economic methodology is substantively identical.
OECD guidance is recognized as persuasive authority in U.S. transfer pricing proceedings and is frequently cited by both taxpayers and the IRS in interpreting the arm's-length standard. The U.S. Treasury Regulations and the OECD Guidelines share a common foundation in the arm's-length principle, and the methods described in each framework are generally consistent in application.
This report applies both the CPM and the TNMM in parallel, recognizing that the analysis may be relevant in both U.S. and Irish contexts. As PBI is an Irish tax resident subject to examination by the Irish Revenue Commissioners, and as the intercompany transactions at issue may also be relevant under Ireland's transfer pricing rules (Taxes Consolidation Act 1997, Part 35A, as amended by the Finance Act 2019), the TNMM analysis is presented alongside the CPM analysis to provide a comprehensive framework for evaluating PBI's arm's-length profitability.
III.D. IRC § 6662(e) — Penalty Protection
Section 6662(e) of the Internal Revenue Code imposes a penalty for substantial valuation misstatements attributable to transfer pricing adjustments under IRC § 482. The penalty is equal to 20% of the underpayment of tax attributable to the misstatement, or 40% in the case of a gross valuation misstatement. However, under IRC § 6662(e)(3)(B), no penalty shall be imposed if the taxpayer establishes that there was reasonable cause for the underpayment and that the taxpayer acted in good faith with respect to such portion.
Contemporaneous documentation was prepared by Crestfield & Associates LLP for all four tax years at issue (TY 2017–2020) in accordance with the requirements of Treasury Regulations § 1.6662-6(d) and IRC § 6662(e) penalty-protection standards. The documentation includes a description of the controlled transactions, a functional analysis of the controlled parties, a selection and application of the best method, and an analysis of the arm's-length range of results under the selected method.
This CPM/TNMM analysis, prepared by WVG under direction of counsel, further supports PPC's reasonable-cause defense under IRC § 6662(e)(3)(B) by providing an independent, rigorous economic analysis confirming that PBI's operating margins fall within the arm's-length range. The existence of both contemporaneous documentation (prepared by Crestfield & Associates at the time of filing) and this independent analysis (prepared in connection with the examination) collectively demonstrate that PPC exercised reasonable care in determining its transfer prices and had a reasonable basis for believing that its transfer pricing positions were consistent with the arm's-length standard.
IV. Methodology
IV.A. Selection of Tested Party
PBI has been selected as the tested party in this CPM/TNMM analysis. The selection of the tested party is governed by Treasury Regulations § 1.482-5(b)(2), which provides that the tested party should be the controlled taxpayer whose profitability can be verified using the most reliable data and requiring the fewest and most reliable adjustments. Ordinarily, the tested party will be the less complex of the controlled parties, i.e., the party whose operations are less integrated with the controlled transactions and for which comparable company data is more readily available.
In this case, PBI is the appropriate tested party for the following reasons:
(a) Identifiable Functions. PBI performs identifiable and well-defined functions, including IP-holding, regional commercialization and distribution, regulatory management across 68 non-Americas country markets, and supply-chain coordination. These functions are commonly performed by independent companies in the pharmaceutical and life sciences sector, facilitating the identification of reliable comparable companies.
(b) Identifiable Risks. PBI bears specific, quantifiable risks that are characteristic of independent pharmaceutical distribution and IP-holding companies, including market risk for non-Americas territories, regulatory risk, foreign exchange risk, and credit risk. These risk characteristics can be matched to comparable companies with similar risk profiles.
(c) Complexity of PPC. PPC, the U.S. entity, is the more complex party within the controlled group. PPC owns unique, high-value intangible property, including core R&D capabilities, drug development expertise, and the workforce in place responsible for the discovery and early-stage development of PPC's pharmaceutical pipeline. The identification of reliable comparables for PPC would require finding independent companies with comparable R&D portfolios, drug development pipelines, and commercialization infrastructure — a task that would be substantially more difficult and would yield less reliable results than benchmarking PBI's profitability.
(d) Data Availability. Reliable publicly available financial data is more readily available for companies performing functions similar to PBI (pharmaceutical distribution principals, IP-holding entities, and regional commercialization companies) than for companies performing functions comparable to PPC's core R&D and global commercialization activities.
For these reasons, testing PBI's profitability under the CPM/TNMM is more reliable than testing PPC's profitability, and PBI is selected as the tested party consistent with the best method rule under Treasury Regulations § 1.482-1(c).
IV.B. Selection of Profit Level Indicator
WVG selects operating margin (operating income divided by net revenue) as the primary PLI for this CPM/TNMM analysis.
Rationale for Operating Margin. Operating margin is the most commonly used PLI for the evaluation of distribution, commercialization principal, and IP-holding companies in the pharmaceutical sector. Operating margin directly measures the relationship between the tested party's revenue and the total costs incurred in performing its functions — including cost of goods sold, operating expenses, selling and marketing costs, general and administrative expenses, and R&D cost-sharing payments — and therefore provides a comprehensive measure of the tested party's overall profitability from its controlled transactions.
Operating margin is appropriate for PBI because PBI's revenue base is substantial and well-defined (consisting of net sales of pharmaceutical products in non-Americas territories), and PBI's operating expenses include a mix of cost of goods sold (payments to PMI under the contract manufacturing arrangement), intercompany cost-sharing payments under the CSA, intercompany royalty payments for legacy IP, and PBI's own regulatory, commercial, and administrative expenses. The operating margin PLI captures the cumulative effect of all of these cost elements on PBI's profitability and therefore provides the most comprehensive test of whether PBI's overall profit level is consistent with the arm's-length standard.
Berry Ratio. The Berry ratio (gross profit divided by operating expenses) was considered as an alternative PLI but was not selected as the primary indicator. The Berry ratio is most useful when the tested party's gross profit is primarily attributable to the value added by the tested party's own functions and is not significantly affected by the value of intangible property or other factors not comparable to those of the uncontrolled comparables. Because PBI holds significant intangible property rights (under the CSA and the legacy IP license), and because PBI's gross profit is influenced by these intangible assets, the Berry ratio may be less reliable than operating margin as the primary PLI. However, the Berry ratio is used as a confirmatory measure, as discussed in Section VI.D.
Return on Assets. Return on operating assets (operating income divided by operating assets) was also considered. Return on assets is appropriate when the tested party deploys significant capital assets in its operations, and when differences in capital intensity between the tested party and the comparables could affect the comparability of operating margins. While PBI does employ capital in its operations (including intangible assets, office facilities, IT infrastructure, and working capital), the operating margin PLI adequately captures the effect of PBI's capital deployment on its profitability. Return on assets is used as a confirmatory measure, as discussed in Section VI.E.
IV.C. Comparable Company Search Strategy
WVG conducted a systematic, multi-step comparable company search to identify independent companies that are functionally comparable to PBI and can serve as benchmarks for the CPM/TNMM analysis. The search process included both quantitative screening criteria (applied to commercial databases of publicly available financial data) and qualitative screening criteria (applied through manual review of company descriptions, financial statements, and annual reports). The complete documentation of the search process, including the number of companies at each stage of the screening funnel, is provided in Appendix C.
IV.C.1. Quantitative Screening Criteria
The initial universe of potential comparable companies was drawn from commercial databases containing publicly available financial data for companies worldwide. WVG applied the following quantitative screening criteria to narrow the universe to a manageable set of potential comparables:
(a) Geographic Scope. The search focused on companies domiciled in Western Europe, with particular emphasis on Ireland, the United Kingdom, the Netherlands, Germany, Switzerland, and other OECD jurisdictions. This geographic focus was selected to ensure that the comparable companies operate in economic environments broadly similar to PBI's operating environment, including comparable regulatory frameworks, market structures, and business conditions.
(b) Industry Focus. The search was limited to companies classified in the pharmaceutical, biotechnology, and life sciences sectors, specifically companies performing IP-holding, distribution, and commercialization functions. Companies operating in unrelated industries (e.g., medical devices, diagnostics, or healthcare services without pharmaceutical distribution or IP-holding activities) were excluded.
(c) Revenue Threshold. A minimum revenue threshold of €100 million was applied to ensure scale comparability with PBI, which reported revenue of approximately €2.14 billion in FY 2020. While exact size matching is not required under the CPM/TNMM, significant size disparities can introduce comparability concerns related to economies of scale, bargaining power, and market position. The €100 million threshold was selected as a reasonable lower bound that excludes micro-cap and small-cap companies whose operating characteristics may differ materially from those of PBI.
(d) Financial Data Availability. Companies were required to have available financial statements for at least three of the four years in the analysis period (2017–2020) to ensure sufficient data for the calculation of year-by-year and multi-year operating margins.
(e) Independence. Companies that are controlled by or affiliated with PPC or any PPC subsidiary were excluded from the comparable set. Additionally, companies that are controlled by other multinational pharmaceutical groups and function as captive subsidiaries (rather than independent market participants) were excluded to the extent that their financial results may not reflect arm's-length economics.
(f) Revenue Concentration. Companies with significant unrelated business activities were excluded. Specifically, companies for which less than 75% of total revenue was derived from pharmaceutical or biotechnology distribution, commercialization, or IP licensing activities were eliminated to ensure that the comparable companies' financial results are primarily driven by activities comparable to PBI's functions.
IV.C.2. Qualitative Screening Criteria
Following the application of quantitative screening criteria, WVG conducted a qualitative review of the remaining companies to assess their functional, risk, and asset comparability to PBI. The qualitative screening criteria included the following:
(a) Functional Comparability. Companies were evaluated based on whether they perform functions similar to those performed by PBI — specifically, functions as regional commercialization principals, pharmaceutical distributors with IP rights, or IP-holding/licensing entities. Companies whose primary functions are limited to manufacturing, basic logistics, or passive investment were excluded.
(b) Risk Profile. Companies were evaluated based on whether they bear risks comparable to those borne by PBI, including market risk, pricing risk, and regulatory risk in their respective territories. Companies operating under limited-risk distribution arrangements (e.g., commissionnaire or toll distribution arrangements) were excluded, as their risk profiles are fundamentally different from PBI's entrepreneurial risk-bearing role.
(c) Asset Comparability. Companies were evaluated based on whether they hold assets comparable to those held by PBI, including intangible assets (marketing intangibles, distribution rights, or licensed pharmaceutical IP) and whether they manage physical distribution or contract manufacturing relationships. Companies with asset profiles materially different from PBI's (e.g., companies with no intangible assets, or companies with large manufacturing operations that dominate their financial results) were excluded.
(d) Loss-Making Companies. Companies reporting operating losses during the analysis period were eliminated unless the losses were attributable to identifiable start-up activities or non-recurring restructuring events, which would make the companies' results non-comparable to PBI's mature, profitable operations.
(e) Extraordinary Items. Companies whose operating margins were materially affected by extraordinary items, non-recurring transactions (such as significant asset impairments, litigation settlements, or business acquisitions/divestitures), or other one-time events were excluded to avoid distortion of the comparable set.
IV.C.3. Final Comparable Set
Following the application of the quantitative and qualitative screening criteria described above, WVG identified a final comparable set of 22 independent companies. These 22 companies represent a cross-section of the pharmaceutical and life sciences industry and include the following types of entities:
• Pharmaceutical distribution principals that hold distribution rights for specific geographic territories and manage commercialization activities within those territories;
• Regional IP-holding entities that hold licensed or self-developed intellectual property and earn royalties, licensing fees, or profit margins from the exploitation of that IP in designated markets;
• Specialty pharmaceutical commercialization companies that focus on the marketing and distribution of specialty and niche pharmaceutical products in European and Asia-Pacific markets; and
• Biotechnology distribution companies that manage the commercialization of biologic therapies and biosimilars in non-U.S. markets.
The 22 comparable companies collectively represent a robust and reliable benchmark for evaluating PBI's operating margins under the CPM/TNMM. Full comparable company profiles, including descriptions of each company's functions, assets, risks, and financial data for 2017–2020, are provided in Appendix B. The complete financial data and screening worksheets are provided in the accompanying benchmarking workbook (benchmarking-study-comparables.xlsx).
IV.D. Adjustments to Comparable Data
To enhance the comparability of the financial data used in this analysis, WVG applied certain adjustments to the operating margins of the 22 comparable companies:
Working Capital Adjustments. WVG applied working capital adjustments to normalize for differences in accounts receivable, accounts payable, and inventory levels between the comparable companies and PBI. Differences in working capital levels can affect operating margins by influencing the imputed financing cost embedded in the tested party's and comparables' operating results. The working capital adjustment methodology is consistent with standard practice under the CPM/TNMM and is described in detail in Appendix E.
Specifically, the working capital adjustment computes an imputed interest charge (or credit) based on the difference between each comparable company's working capital level and the median working capital level of the comparable set, applied at a market interest rate. The imputed interest charge is then added to (or subtracted from) the comparable company's operating income to arrive at an adjusted operating margin. This adjustment ensures that differences in financing terms, collection practices, and inventory management do not distort the comparability of operating margins across the comparable set.
Treatment of R&D Expenditures. Certain comparable companies in the benchmarking set incur self-funded research and development expenditures that differ in magnitude from PBI's R&D-related costs (which consist primarily of cost-sharing payments under the CSA rather than direct self-funded R&D). WVG evaluated the impact of these differences and, where appropriate, made adjustments to eliminate or normalize for the effect of self-funded R&D expenditures on comparable companies' operating margins. The specific adjustments applied to individual comparable companies are documented in the benchmarking workbook.
Geographic Adjustments. No adjustment was made for geographic differences where the comparable companies operate in comparable OECD markets. The comparable companies in the benchmarking set are predominantly domiciled in Western European jurisdictions with regulatory frameworks, market structures, and economic conditions broadly comparable to those in which PBI operates. WVG concluded that no material geographic comparability issues exist that would warrant a quantitative adjustment.
IV.E. Determination of Arm's-Length Range
Consistent with the guidance in Treasury Regulations § 1.482-1(e)(2)(iii)(C) and OECD Transfer Pricing Guidelines paragraph 3.57, WVG uses the interquartile range ("IQR") as the arm's-length range for this CPM/TNMM analysis. The IQR is defined as the range of results between the 25th percentile and the 75th percentile of the comparable company operating margins.
The use of the IQR is appropriate because, while the 22 comparable companies are reasonably comparable to PBI, minor differences in functions, risks, and economic circumstances among the comparables (and between the comparables and PBI) may affect operating margins. The IQR narrows the range of comparable results to focus on the central tendency of the data, thereby reducing the impact of any residual comparability differences on the arm's-length range.
WVG calculated the 25th percentile, median (50th percentile), and 75th percentile of operating margins for the 22 comparable companies for each individual tax year (2017, 2018, 2019, and 2020) and for the multi-year weighted average across the four-year period. The multi-year weighted average is calculated by weighting each comparable company's operating margin by its revenue in each year, consistent with the approach recommended in Treasury Regulations § 1.482-5(b)(4)(i) and OECD Guidelines paragraph 3.75 for smoothing year-to-year fluctuations and providing a more reliable measure of the arm's-length range.
IV.F. Testing PBI's Operating Margin
WVG compared PBI's actual operating margins for TY 2017, 2018, 2019, and 2020 to the IQR of the comparable set for the corresponding periods. PBI's operating margins were derived from PBI's Irish statutory financial statements, which report revenue, cost of sales, operating expenses, and operating income in accordance with Irish Generally Accepted Accounting Principles ("Irish GAAP") and Financial Reporting Standard 102 ("FRS 102").
The CPM/TNMM standard provides that if the tested party's operating margin falls within the IQR of the comparable set, the intercompany pricing is within the arm's-length range and no adjustment is warranted under IRC § 482. Conversely, if the tested party's operating margin falls outside the IQR, an adjustment may be warranted to bring the tested party's result to the median or another point within the arm's-length range. As discussed in Section VI, PBI's operating margins fall within the IQR for all four tax years and for the multi-year weighted average, confirming that no adjustment is warranted.
V. Functional Analysis of PBI (Summary)
V.A. Overview
A comprehensive functional analysis of PBI has been prepared separately and is documented in the functional analysis reports prepared by WVG under the direction of counsel (functional-analysis-report.docx and functional-analysis-report-updated.docx). The functional analysis describes in detail PBI's functions performed, assets employed, and risks assumed in connection with its role as IP-holding company and commercialization principal for PPC's pharmaceutical product portfolio in non-Americas territories.
This section presents a summary of PBI's functional profile relevant to the CPM/TNMM analysis. The characterization of PBI's functions, assets, and risks is critical to the selection of comparable companies and the evaluation of PBI's operating margins against the arm's-length range.
V.B. Key Functions Performed by PBI
PBI performs the following key functions in connection with its role as IP-holding company and non-Americas commercialization principal:
Regulatory Affairs. PBI manages regulatory submissions and marketing authorization applications across 68 non-Americas country markets, including the centralized European Medicines Agency ("EMA") procedure for EU-wide approvals, national marketing authorization procedures in non-EU jurisdictions, and ongoing regulatory compliance activities including post-marketing surveillance, pharmacovigilance, and regulatory variations. PBI's cumulative regulatory expenditures on submissions for non-Americas markets during the 2017–2020 period totaled €47.2 million. PBI employs a team of regulatory affairs professionals in Dublin who are responsible for preparing and managing regulatory submissions, responding to regulatory authority queries, and ensuring ongoing compliance with local regulatory requirements in each country market.
Commercial Strategy. PBI makes independent pricing and market-entry decisions for PPC's products in non-Americas territories. PBI's commercial strategy team determines the pricing of PPC products in each country market, taking into account local competitive dynamics, government pricing and reimbursement frameworks, health technology assessment outcomes, and market demand. PBI selects and manages distribution partners in markets where PBI does not maintain a direct commercial presence, and negotiates distribution agreements on arm's-length terms. PBI also manages product launches, including the sequencing of launches across country markets, the development of market access strategies, and the coordination of medical education and promotional activities.
Medical Affairs. PBI employs medical science liaisons ("MSLs") and medical affairs professionals in Dublin and in selected country markets. PBI's medical affairs team manages post-marketing surveillance activities, medical education programs, and scientific communications related to PPC's products in non-Americas territories. PBI's medical affairs function also supports regulatory submissions by contributing clinical data and scientific expertise.
Supply Chain Management. PBI manages the contract manufacturing relationship with PMI (cost-plus 8%) and oversees the logistics and distribution of PPC's products across EMEA and APAC markets. PBI's supply chain team coordinates production planning, inventory management, quality assurance, and distribution to ensure timely and reliable supply of PPC's products to customers and distribution partners in non-Americas territories.
IP Exploitation. PBI holds rights under the CSA to exploit PPC's pharmaceutical IP portfolio outside the Americas. PBI also holds licensed rights to PPC's legacy compounds (pre-2012 vintage) under the legacy IP royalty arrangement at 4.5% of net sales. PBI's exploitation of these intangible assets is the primary driver of its revenue and profitability.
V.C. Key Assets Held by PBI
PBI holds the following key categories of assets:
• Intangible Assets: Rights under the CSA to exploit PPC's pharmaceutical IP portfolio in non-Americas territories; licensed rights to legacy compounds under the 4.5% royalty arrangement; marketing intangibles developed through PBI's commercialization activities (including customer relationships, distribution networks, and market knowledge).
• Tangible Assets: Office facilities at Sandyford Business Park, Dublin (approximately 18,000 square feet); information technology infrastructure, including enterprise resource planning systems, regulatory information management systems, and commercial analytics platforms; office equipment and furniture.
• Financial Assets: Cash and bank deposits maintained with Glenmore Bank Ireland plc; working capital (accounts receivable, inventory, and accounts payable); foreign currency hedging instruments.
V.D. Key Risks Borne by PBI
PBI bears the following key categories of risk in connection with its operations:
• Market Risk: PBI bears the risk of demand fluctuations, competitive pressures, and pricing/reimbursement changes in 68 non-Americas country markets. Market risk includes the risk that PBI's products may lose market share to competing therapies, biosimilars, or generic alternatives, and the risk that government pricing and reimbursement authorities may reduce or deny reimbursement for PBI's products.
• Regulatory Risk: PBI bears the risk of regulatory setbacks, including approval delays, label restrictions, post-marketing requirements, and product recalls. Regulatory risk is significant in the pharmaceutical industry, as the commercialization of pharmaceutical products in any jurisdiction is contingent on obtaining and maintaining marketing authorization from the applicable regulatory authority.
• Foreign Exchange Risk: PBI's operations are denominated in euros, but PBI generates revenue in multiple currencies across its 68 country markets. PBI bears the risk of adverse currency movements that may reduce the euro-equivalent value of its non-euro revenue. PBI manages foreign exchange risk through hedging instruments maintained with Glenmore Bank Ireland plc, but residual foreign exchange risk remains.
• Credit Risk: PBI bears the risk of non-payment or delayed payment by its distribution partners and customers in non-Americas territories.
• Product Liability Risk: PBI shares product liability risk with PPC under intercompany indemnification agreements. PBI bears primary product liability exposure in non-Americas territories and is responsible for managing product liability claims and regulatory actions in its markets.
V.E. Characterization of PBI for CPM/TNMM Purposes
Based on the functional analysis summarized above, PBI is characterized as an IP-holding/commercialization principal performing significant DEMPE functions. PBI is not a limited-risk distributor, commissionnaire, or conduit entity. Rather, PBI is an entrepreneurial entity that bears genuine economic risks — including market risk, regulatory risk, and foreign exchange risk — and exercises significant management control over the commercialization of PPC's products in non-Americas territories.
This characterization is supported by PBI's headcount of 185 employees, its independent pricing authority across 68 country markets, its cumulative regulatory expenditures of €47.2 million during 2017–2020, and the 42 board meetings held in Dublin during the period at issue. The characterization is further supported by the interviews of 12 key PBI employees conducted by C&H, which confirmed that PBI personnel exercise genuine, independent judgment and decision-making authority.
This characterization drives the selection of comparable companies with similar risk profiles and functional intensity. The comparable companies in the benchmarking set (described in Section IV.C and Appendix B) are independent companies that perform IP-holding, distribution principal, and regional commercialization functions, bear entrepreneurial risk in their respective territories, and earn operating margins commensurate with their functions and risks. PBI's profitability is evaluated against these comparable companies to test whether PBI's operating margins fall within the arm's-length range.
VI. Results of the CPM / TNMM Analysis
VI.A. Comparable Company Operating Margin Results
The following table presents the summary statistics of operating margins for the 22 comparable companies for each year in the analysis period and the multi-year weighted average. The underlying operating margin data for each individual comparable company, together with the financial data from which those margins were derived, is provided in the benchmarking workbook (benchmarking-study-comparables.xlsx) and in the individual comparable company profiles in Appendix B.
Table VI-1: Comparable Company Operating Margin Summary Statistics (2017–2020)
The interquartile range ("IQR") for each year is defined by the 25th percentile and 75th percentile values shown above. The IQR represents the range of operating margins within which PBI's results are compared to evaluate arm's-length consistency.
The comparable company operating margins exhibit reasonable stability across the four-year period, reflecting the generally stable demand conditions and pricing environment in the pharmaceutical sector during 2017–2020. The slight downward movement in 2020 margins for certain comparables is consistent with the impact of the COVID-19 pandemic on elective medical procedures and patient access to healthcare services, which affected demand for certain pharmaceutical products during that year.
VI.B. PBI's Operating Margins (2017–2020)
The following table presents PBI's operating margins for each year in the analysis period, derived from PBI's Irish statutory financial statements:
Table VI-2: PBI Operating Margins (2017–2020)
PBI's operating expenses include cost-sharing payments under the CSA, royalty payments for legacy IP, selling and marketing expenses, regulatory affairs expenditures, general and administrative expenses, and other operating costs. PBI's cost of sales consists primarily of payments to PMI under the contract manufacturing arrangement (cost-plus 8%).
PBI's revenue has grown steadily during the 2017–2020 period, reflecting the increasing market penetration of PPC's key products (Veritaxol, Imvara, and Cerulon) in non-Americas territories. Non-Americas net sales for the three principal products in FY 2020 were: Veritaxol $1.34 billion, Imvara $0.79 billion, and Cerulon $0.28 billion. Revenue from legacy compounds has declined over the period, partially offsetting the growth in newer product revenue.
PBI's operating margin has remained remarkably stable at approximately 31.5% throughout the four-year period, reflecting the consistent relationship between PBI's revenue growth and the corresponding increase in its cost base (including proportionally increasing cost-sharing payments under the CSA).
VI.C. Comparison: PBI Margins vs. Arm's-Length Range
The following table compares PBI's operating margins to the IQR of the comparable company set for each year and the multi-year weighted average:
Table VI-3: PBI Operating Margin vs. Arm's-Length Range (IQR)
For each of the four tax years at issue, and for the multi-year weighted average, PBI's operating margin falls within the IQR of the comparable company set. PBI's operating margin of approximately 31.5% is above the median but well within the 75th percentile, indicating that PBI earns profits that are consistent with — but not at the extreme upper end of — the range of profits earned by comparable independent companies.